Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer

3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme in cholesterol biosynthesis pathway that has been associated with cancer development. Although the connection between HMGCR and HER2 has been established, the function of HMGCR in the advanced progression of HER2 pos...

Full description

Saved in:

Bibliographic Details
Main Author:	Drahman, Rosmaizan
Format:	Thesis
Language:	English
Published:	2022
Subjects:	R Medicine
Online Access:	http://eprints.usm.my/57613/1/ROSMAIZAN%20BINTI%20DRAHMAN-FINAL%20THESIS%20P-UM000418%28R%29-24%20pages.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.57613
record_format	uketd_dc
spelling	my-usm-ep.576132023-03-29T02:15:07Z Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer 2022-05 Drahman, Rosmaizan R Medicine RC254-282 Neoplasms. Tumors. Oncology (including Cancer) 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme in cholesterol biosynthesis pathway that has been associated with cancer development. Although the connection between HMGCR and HER2 has been established, the function of HMGCR in the advanced progression of HER2 positive breast cancer and anti HER2 therapy resistance remains unknown. The purpose of this research is to study the expression of HMGCR in HER2 positive and HER2 negative breast cancer and to determine the association between HMGCR expression and clinicopathological characteristics of breast cancer patients. Breast cancer cell lines MDA-MB-453 and MDA-MB-361 (HER2 positive), MDA-MB-231 and MCF-7 (HER2 negative) were cultured in DMEM media supplemented with 4% FBS and 1% antibiotic. When the cells reached confluence, they were subcultured in Petri dishes for protein extraction and western blotting. In addition, the levels of HMGCR mRNA were determined by qPCR analysis on FFPE (formalin fixed paraffin embedded) breast cancer tissues with IHC scores of HER2 0, HER2 1+, HER2 2+ and HER2 3+. Moreover, HMGCR immunohistochemistry (IHC) staining was conducted on FFPE HER2 positive and HER2 negative breast cancer tissues. In comparison to other breast cancer cell lines, the HER2 positive cell line MDA-MB-453 had a high level of basal HMGCR protein (p=0.011). Furthermore, HMGCR mRNA expression was much greater in HER2 IHC 3+ breast cancer samples than in other HER2 breast cancer subtypes, but this difference was not statistically significant (p=0.118). According to the IHC study, the percentage of HER2 IHC 3+ samples with high HMGCR protein expression was 88.9 % (32 out of 36 cases), which was considerably greater than the percentage of HER2 IHC 0 & 1+ samples with high HMGCR protein expression of 69.4 % (25 out of 36 cases) (p=0.042). However, the association analysis revealed that the majority of breast cancer cases with high HMGCR expression were among samples with HER2 positivity, a larger tumour size (> 2cm), high scores (Score 2 and Score 3) on tumour grade parameters such as nuclear pleomorphism, tubular formation, and mitotic count, a higher tumour grade (Grade 2 and Grade 3), ER positivity, PR negativity, and the presence of lymph node involvement. The correlations, however, were not statistically significant. Our results contribute to the existing body of knowledge on the link between HMGCR expression and HER2 positive breast cancer. Further research should be conducted to determine the molecular connections between HMGCR and HER2 positive breast cancer in relation to tumour development and resistance to anti-HER2 treatment in HER2 positive breast cancer. 2022-05 Thesis http://eprints.usm.my/57613/ http://eprints.usm.my/57613/1/ROSMAIZAN%20BINTI%20DRAHMAN-FINAL%20THESIS%20P-UM000418%28R%29-24%20pages.pdf application/pdf en public masters Universiti Sains Malaysia Pusat Pengajian Sains Perubatan
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	R Medicine R Medicine
spellingShingle	R Medicine R Medicine Drahman, Rosmaizan Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
description	3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme in cholesterol biosynthesis pathway that has been associated with cancer development. Although the connection between HMGCR and HER2 has been established, the function of HMGCR in the advanced progression of HER2 positive breast cancer and anti HER2 therapy resistance remains unknown. The purpose of this research is to study the expression of HMGCR in HER2 positive and HER2 negative breast cancer and to determine the association between HMGCR expression and clinicopathological characteristics of breast cancer patients. Breast cancer cell lines MDA-MB-453 and MDA-MB-361 (HER2 positive), MDA-MB-231 and MCF-7 (HER2 negative) were cultured in DMEM media supplemented with 4% FBS and 1% antibiotic. When the cells reached confluence, they were subcultured in Petri dishes for protein extraction and western blotting. In addition, the levels of HMGCR mRNA were determined by qPCR analysis on FFPE (formalin fixed paraffin embedded) breast cancer tissues with IHC scores of HER2 0, HER2 1+, HER2 2+ and HER2 3+. Moreover, HMGCR immunohistochemistry (IHC) staining was conducted on FFPE HER2 positive and HER2 negative breast cancer tissues. In comparison to other breast cancer cell lines, the HER2 positive cell line MDA-MB-453 had a high level of basal HMGCR protein (p=0.011). Furthermore, HMGCR mRNA expression was much greater in HER2 IHC 3+ breast cancer samples than in other HER2 breast cancer subtypes, but this difference was not statistically significant (p=0.118). According to the IHC study, the percentage of HER2 IHC 3+ samples with high HMGCR protein expression was 88.9 % (32 out of 36 cases), which was considerably greater than the percentage of HER2 IHC 0 & 1+ samples with high HMGCR protein expression of 69.4 % (25 out of 36 cases) (p=0.042). However, the association analysis revealed that the majority of breast cancer cases with high HMGCR expression were among samples with HER2 positivity, a larger tumour size (> 2cm), high scores (Score 2 and Score 3) on tumour grade parameters such as nuclear pleomorphism, tubular formation, and mitotic count, a higher tumour grade (Grade 2 and Grade 3), ER positivity, PR negativity, and the presence of lymph node involvement. The correlations, however, were not statistically significant. Our results contribute to the existing body of knowledge on the link between HMGCR expression and HER2 positive breast cancer. Further research should be conducted to determine the molecular connections between HMGCR and HER2 positive breast cancer in relation to tumour development and resistance to anti-HER2 treatment in HER2 positive breast cancer.
format	Thesis
qualification_level	Master's degree
author	Drahman, Rosmaizan
author_facet	Drahman, Rosmaizan
author_sort	Drahman, Rosmaizan
title	Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
title_short	Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
title_full	Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
title_fullStr	Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
title_full_unstemmed	Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
title_sort	evaluating the expression of hmgcr in her2 negative and her2 positive breast cancer
granting_institution	Universiti Sains Malaysia
granting_department	Pusat Pengajian Sains Perubatan
publishDate	2022
url	http://eprints.usm.my/57613/1/ROSMAIZAN%20BINTI%20DRAHMAN-FINAL%20THESIS%20P-UM000418%28R%29-24%20pages.pdf
_version_	1776101202627395584

Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer

Similar Items